Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, Republic of Korea.
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea.
Rheumatol Int. 2018 Apr;38(4):649-656. doi: 10.1007/s00296-017-3925-9. Epub 2018 Jan 4.
The objectives of this study are to identify the prevalence and incidence of rheumatoid arthritis (RA) and to investigate the patterns of medical care and drug utilization by RA patients in Korea. Korean National Health Insurance claims data were used for analysis. RA patients were defined as those having an RA code from 2009 to 2012 and using disease-modifying anti-rheumatic drugs (DMARDs) within 1 year after the code. RA patients identified in 2010 with a disease-free period for 12 months before the index date, and those who received continuous treatment in 2011-2013 were defined as incident cases. Patterns of medical care and drug utilization were compared among subgroups. The prevalence of RA increased yearly from 0.28% in 2009 to 0.32% in 2012. The incidence of RA in 2010 was 28.5 per 100,000 person-years. The use of biologic DMARDs (bDMARDs) increased from 2.31% in 2009 to 4.05% in 2012. Hydroxychloroquine (57.53-62.45%) was the most commonly used the conventional DMARDs, followed by methotrexate (49.99-51.87%). The use of bDMARDs (1.39 vs. 2.43%) was less frequent in EORA patients than YORA patients. Hydroxychloroquine (74.96 vs. 72.11%) was more frequently used, but methotrexate (55.24 vs. 59.25%) and sulfasalazine (27.96 vs. 32.72%) were used less frequently in EORA patients than in YORA patients. The prevalence of RA has increased in Korea. EORA patients used fewer bDMARDs, methotrexate, and sulfasalazine but more hydroxychloroquine than YORA patients.
本研究旨在明确类风湿关节炎（RA）的患病率和发病率，并调查韩国 RA 患者的医疗模式和药物使用情况。我们使用韩国国民健康保险理赔数据进行分析。RA 患者的定义为 2009 年至 2012 年期间使用 RA 代码且在该代码后 1 年内使用疾病修饰抗风湿药物（DMARDs）的患者。2010 年确诊的 RA 患者，在指数日期前 12 个月无疾病史，且 2011 年至 2013 年期间持续接受治疗的患者被定义为新发病例。比较了亚组间的医疗模式和药物使用情况。RA 的患病率从 2009 年的 0.28%逐年增加至 2012 年的 0.32%。2010 年 RA 的发病率为 28.5/100,000 人年。生物 DMARDs（bDMARDs）的使用率从 2009 年的 2.31%增加至 2012 年的 4.05%。羟氯喹（57.53%-62.45%）是最常用的传统 DMARDs，其次是甲氨蝶呤（49.99%-51.87%）。EORA 患者使用 bDMARDs（1.39% vs. 2.43%）的频率低于 YORA 患者。EORA 患者使用羟氯喹（74.96% vs. 72.11%）的频率更高，但使用甲氨蝶呤（55.24% vs. 59.25%）和柳氮磺胺吡啶（27.96% vs. 32.72%）的频率更低。韩国 RA 的患病率呈上升趋势。EORA 患者使用 bDMARDs、甲氨蝶呤和柳氮磺胺吡啶的频率低于 YORA 患者，但使用羟氯喹的频率高于 YORA 患者。
